Published online before print February 9, 2007, doi: 10.1161/01.RES.0000259579.35787.4e
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 13, 2006
Revised on January 20, 2007
Accepted on January 25, 2007
Increasing Survival of Ischemic Tissue by Targeting CD47
Jeff S. Isenberg *;
From the Laboratory of Pathology (J.S.I., M.J.R., M.A.-A., M.T., D.D.R.) and Radiation Biology Branch (D.A.W.), Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Md; and Department of Biochemistry and Molecular Biophysics (A.O., L.P., W.A.F.), Washington University School of Medicine, St Louis, Mo.
* To whom correspondence should be addressed. E-mail: isenberj{at}mail.nih.gov.
Thrombospondin-1 (TSP1) limits the angiogenic and vasodilator activities of NO. This activity of TSP1 can be beneficial in some disease states, but endogenous TSP1 limits recovery of tissue perfusion following fixed ischemic injury in dorsal skin flaps in mice. Using mice lacking the TSP1 receptors CD36 or CD47, we now show that CD47 is the necessary receptor for limiting NO-mediated vascular smooth muscle relaxation and tissue survival following ischemic injury in skin flaps and hindlimbs. We further show that blocking CD47 or TSP1 using monoclonal antibodies and decreasing CD47 expression using an antisense morpholino oligonucleotide are effective therapeutic approaches to dramatically increase survival of soft tissue subjected to fixed ischemia. These treatments facilitate rapid vascular remodeling to restore tissue perfusion and increase skin and muscle viability. Thus, limiting CD47-dependent antagonism of NO-mediated vasodilation and vascular remodeling is a promising therapeutic modality to preserve tissues subject to ischemic stress.
Key words: nitric oxide • thrombospondin-1 • ischemic tissue survival • CD47 • therapeutics
Related Article:
- Targeting CD47: NO Limit on Therapeutic Potential
- David J. Kaczorowski and Timothy R. Billiar
Circ. Res. 2007 100: 602-603.[Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  G. Martin-Manso, S. Galli, L. A. Ridnour, M. Tsokos, D. A. Wink, and D. D. Roberts Thrombospondin 1 Promotes Tumor Macrophage Recruitment and Enhances Tumor Cell Cytotoxicity of Differentiated U937 Cells Cancer Res., September 1, 2008; 68(17): 7090 - 7099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Silvestre, Z. Mallat, A. Tedgui, and B. I. Levy Post-ischaemic neovascularization and inflammation Cardiovasc Res, May 1, 2008; 78(2): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Isenberg, D. D. Roberts, and W. A. Frazier CD47: A New Target in Cardiovascular Therapy Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Isenberg, F. Hyodo, L. K. Pappan, M. Abu-Asab, M. Tsokos, M. C. Krishna, W. A. Frazier, and D. D. Roberts Blocking Thrombospondin-1/CD47 Signaling Alleviates Deleterious Effects of Aging on Tissue Responses to Ischemia Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2582 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Moura, M. Tjwa, P. Vandervoort, K. Cludts, and M. F. Hoylaerts Thrombospondin-1 Activates Medial Smooth Muscle Cells and Triggers Neointima Formation Upon Mouse Carotid Artery Ligation Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2163 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. I. Stenina, E. J. Topol, and E. F. Plow Thrombospondins, Their Polymorphisms, and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1886 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kaczorowski and T. R. Billiar Targeting CD47: NO Limit on Therapeutic Potential Circ. Res., March 16, 2007; 100(5): 602 - 603. [Full Text] [PDF]
|
|